검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy) Kyverna Therapeutics·CD19 11 trials |
|---|---|
Overview Program | KYV-101 anti-CD19 CAR-T cell therapy |
Overview Company | Kyverna Therapeutics |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Lupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted safety switches, and antigen |
MoA Biomarker | CD19 CAR T-cell therapy resets neutrophil gene expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | Next-generation CAR platforms-including regulatory CAR T cells, brain-targeted safety switches, and antigen-specific modulators-may enhance precision and mitigate neurotoxicity, a critical concern in patients with neurologically vulnerable conditions. |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation.. Chimeric antigen receptor (CAR) T-cell therapy is emerging as a promising approach to overcome the limitations of current B-cell-targeted treatments for multiple sclerosis (MS), particularly in progressive forms where disease-modifying therapies (DMTs) often fail to halt neuroinflammation a… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy) Kyverna Therapeutics·CD19 11 trials |
|---|---|
Overview Program | KYV-101 anti-CD19 CAR-T cell therapy |
Overview Company | Kyverna Therapeutics |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Lupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted safety switches, and antigen |
MoA Biomarker | CD19 CAR T-cell therapy resets neutrophil gene expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | Next-generation CAR platforms-including regulatory CAR T cells, brain-targeted safety switches, and antigen-specific modulators-may enhance precision and mitigate neurotoxicity, a critical concern in patients with neurologically vulnerable conditions. |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation.. Chimeric antigen receptor (CAR) T-cell therapy is emerging as a promising approach to overcome the limitations of current B-cell-targeted treatments for multiple sclerosis (MS), particularly in progressive forms where disease-modifying therapies (DMTs) often fail to halt neuroinflammation a… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교